File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study

TitleBeneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study
Authors
Issue Date2006
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schres
Citation
Schizophrenia Research, 2006, v. 88 n. 1-3, p. 102-110 How to Cite?
AbstractBackground: Previous studies suggest that the serotonin-3 (5-HT 3) receptor antagonist ondansetron possesses the therapeutic potential for schizophrenia. This study was designed to determine whether ondansetron as an adjunct to haloperidol could enhance the clinical efficacy and reduce the adverse side effects in chronic treatment-resistant schizophrenia. Methods: Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N = 63) or a fixed dose of 8 mg/day of ondansetron (N = 58) for 12 weeks. Efficacy was defined as the change from baseline to endpoint in score on overall scale and subscales of the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Side effects were evaluated using the Treatment Emergent Symptom Scale and Extrapyramidal Symptom Rating Scale. Results: Ondansetron combined with haloperidol produced a significantly greater improvement on PANSS overall scale and subscales for negative symptoms, general psychopathology, and cognition at endpoint compared to placebo with haloperidol, but no between-treatment group difference was observed on the subscale for positive symptoms and CGI-S. The ondansetron-treated group had a significantly higher proportion of patients with a 30% or greater baseline-to-endpoint reduction in PANSS total score than placebo. Patients in adjunctive ondansetron therapy also experienced significantly lower incidence and severity of parkinsonism and akathisia as well as fewer behavioral hyperactivity, cardiac, and gastrointestinal side effects. Conclusions: Ondansetron is an effective adjunctive agent in enhancing the effectiveness and reducing some adverse side effects of antipsychotic therapy for chronic, treatment-resistant schizophrenia, particularly for negative and cognitive symptoms. © 2006 Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/179436
ISSN
2015 Impact Factor: 4.453
2015 SCImago Journal Rankings: 2.304
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhang, ZJen_US
dc.contributor.authorKang, WHen_US
dc.contributor.authorLi, Qen_US
dc.contributor.authorWang, XYen_US
dc.contributor.authorYao, SMen_US
dc.contributor.authorMa, AQen_US
dc.date.accessioned2012-12-19T09:56:34Z-
dc.date.available2012-12-19T09:56:34Z-
dc.date.issued2006en_US
dc.identifier.citationSchizophrenia Research, 2006, v. 88 n. 1-3, p. 102-110en_US
dc.identifier.issn0920-9964en_US
dc.identifier.urihttp://hdl.handle.net/10722/179436-
dc.description.abstractBackground: Previous studies suggest that the serotonin-3 (5-HT 3) receptor antagonist ondansetron possesses the therapeutic potential for schizophrenia. This study was designed to determine whether ondansetron as an adjunct to haloperidol could enhance the clinical efficacy and reduce the adverse side effects in chronic treatment-resistant schizophrenia. Methods: Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N = 63) or a fixed dose of 8 mg/day of ondansetron (N = 58) for 12 weeks. Efficacy was defined as the change from baseline to endpoint in score on overall scale and subscales of the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity (CGI-S). Side effects were evaluated using the Treatment Emergent Symptom Scale and Extrapyramidal Symptom Rating Scale. Results: Ondansetron combined with haloperidol produced a significantly greater improvement on PANSS overall scale and subscales for negative symptoms, general psychopathology, and cognition at endpoint compared to placebo with haloperidol, but no between-treatment group difference was observed on the subscale for positive symptoms and CGI-S. The ondansetron-treated group had a significantly higher proportion of patients with a 30% or greater baseline-to-endpoint reduction in PANSS total score than placebo. Patients in adjunctive ondansetron therapy also experienced significantly lower incidence and severity of parkinsonism and akathisia as well as fewer behavioral hyperactivity, cardiac, and gastrointestinal side effects. Conclusions: Ondansetron is an effective adjunctive agent in enhancing the effectiveness and reducing some adverse side effects of antipsychotic therapy for chronic, treatment-resistant schizophrenia, particularly for negative and cognitive symptoms. © 2006 Elsevier B.V. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schresen_US
dc.relation.ispartofSchizophrenia Researchen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntipsychotic Agents - Pharmacokinetics - Therapeutic Useen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshDiagnostic And Statistical Manual Of Mental Disordersen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshFemaleen_US
dc.subject.meshHaloperidol - Pharmacokinetics - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOndansetron - Pharmacokinetics - Therapeutic Useen_US
dc.subject.meshSchizophrenia - Diagnosis - Drug Therapyen_US
dc.titleBeneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailZhang, ZJ: zhangzj@hkucc.hku.hken_US
dc.identifier.authorityZhang, ZJ=rp01297en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.schres.2006.07.010en_US
dc.identifier.pmid16959472-
dc.identifier.scopuseid_2-s2.0-33750609681en_US
dc.identifier.hkuros135456-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33750609681&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume88en_US
dc.identifier.issue1-3en_US
dc.identifier.spage102en_US
dc.identifier.epage110en_US
dc.identifier.isiWOS:000242719900013-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridZhang, ZJ=8061473900en_US
dc.identifier.scopusauthoridKang, WH=10143941200en_US
dc.identifier.scopusauthoridLi, Q=36072924100en_US
dc.identifier.scopusauthoridWang, XY=7501875577en_US
dc.identifier.scopusauthoridYao, SM=15053852100en_US
dc.identifier.scopusauthoridMa, AQ=55421352700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats